- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis
- Interventions
- Magnetic resonance imaging (MRI), Magnetic resonance elastography (MRE), Prototype MRE soft flexible passive transducer paddle
- Diagnostic Test · Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 1 Week to 40 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 553–562
of 562
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
- Interventions
- Alpelisib 300 mg, Placebo, [1-13C] sodium acetate, [6,6-2H2] D-glucose, Mixed Meal Tolerance Test, Nestlé BOOST Plus
- Drug · Diagnostic Test · Dietary Supplement
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- intraconazole, Rifampin, EDP 305
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- NASH, NAFLD, Non-alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Fatty Liver, Fatty Liver Disease
- Interventions
- Thermo-acuostic image acquisition of liver, MRI-PDFF estimation of hepatic fat
- Diagnostic Test
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Experimental: Low-fructose, reduced carbohydrate diet, General Healthy Diet
- Behavioral
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 11 Years to 17 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Non-Alcoholic Steatohepatitis (NASH)
- Interventions
- Pemvidutide, Placebo
- Drug
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 29
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 23 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- GR-MD-02, Placebo
- Drug
- Lead sponsor
- Galectin Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
- Interventions
- Aspirin 81 mg, Placebo oral tablet
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-alcoholic Steatohepatitis NASH
- Interventions
- LMB763, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 14
- States / cities
- Culver City, California • Cypress, California • Gainesville, Florida + 10 more
- Conditions
- Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
- Interventions
- Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
- Drug · Diagnostic Test · Dietary Supplement + 1 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York